Aijun Liao, M.D., Ph.D.

626-218-5628
Aijun Liao, M.D., Ph.D.
Visiting Scholar, Department of Systems Biology
Clinical Expertise
  • Cell Culturing
  • Western Blot
  • Real Time PCR
  • Flow Cytometry
  • MTT
Research Area
  • Genetic Alterations and CLL Biology
Aijun Liao completed her M.D. and Ph.D. from China Medical University, China. As a physician scientist in China, her research focused on the biology of leukemia, lymphoma and multiple myeloma. As a visiting scholar in the Lili Wang Lab, she is currently investigating functional impacts of genetic lesions on B cells and their contributions to CLL.

Location

Education & Experience

Degrees

  • 2018-Present, visiting scholar, City of Hope, Duarte, CA

  • 2005, Ph.D., Pathology and Pathophysiology, China Medical University, China

  • 1999, M.S., Internal Medicine, China Medical University, China

  • 1994, B.S., Pediatrics , China Medical University, China

Professional Experience

  • 2018-Present, Visiting Scholar, Department of Systems Biology, Beckman Research Institute of City of Hope, City of Hope, Duarte, CA

  • 2012-2018, Professor, Department of Hematology, Shengjing Hospital of China Medical University, China

  • 2009-2010, Visiting Scholar, Penn State Cancer Institute, Hershey, PA

  • 2006-2012, Associate Professor, Department of Hematology, Shengjing Hospital of China Medical University, China

  • 2002-2006, Attending Physician, Department of Hematology, Shengjing Hospital of China Medical University, China

  • 1994-2002, Resident, Department of Hematology, Shengjing Hospital of China Medical University, China

Awards & Memberships

Memberships

  • Hematology Association of Chinese Medical Doctor Association (Multiple Myeloma Group)

  • Hematology Association of Chinese Geriatrics Society (Multiple Myeloma Group)

  • Hematology Association of Chinese Medical Association (9th and 10th Chapter of the Infectious Diseases Group)

  • Chinese Society of Immunology (4th Chapter)

  • Chinese Academy of Research-Oriented Hospital Committee on Precise Treatment of Hematopathy

  • Liaoning Medical Association (Hematology)

  • Liaoning Institute of Hematology and Immunology (Deputy Director)

  • China Cancer Association, Liaoning Branch (Lymphoma Specialized Committee)

Publications

  • Yang R, Huang J, Ma H, Li S, Gao X, Liu Y, Shen J, Liao A#.Is complement C1q a potential marker for tumor burden and immunodeficiency in multiple myeloma? Leuk Lymphoma. 2019 Jan 10:1-7.
  • Fu D, Li Y, Li J, Shi X, Yang R, Zhong Y, Wang H, Liao A#. The effect of S1P receptor signaling pathway on the survival and drug resistance in multiple myeloma cells. Mol Cell Biochem. 2017 Jan;424(1-2):185-193.
  • Liu H, Wang H, Wu B, Yao K, Liao A, Miao M, Li Y, Yang W. Down-regulation of long non-coding RNA MALAT1 by RNA interference inhibits proliferation and induces apoptosis in multiple myeloma. Clin Exp Pharmacol Physiol. 2017 Oct;44(10):1032-1041.
  • Wang H, Wang X, Liao A, Liu Z. Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway. Mol Cell Biochem. 2017 Sep;433(1-2):141-148.
  • Wang H, Wang X, Xin N, Qi L, Liao A, Yang W, Liu Z, Zhao C. Live kinase B1 maintains CD34+CD38- AML cell proliferation and self-renewal. Mol Cell Biochem. 2017 Oct;434(1-2):25-32.
  • Liao A, Hu R, Zhao Q, Li J, Li Y, Yao K, Zhang R, Wang H, Yang W, Liu Z. Autophagy induced by FTY720 promotes apoptosis in U266 cells. Eur J Pharm Sci. 2012 Apr 11;45(5):600-5.
  • Saadatpour A, Wang RS, Liao A, Liu X, Loughran TP, Albert I, Albert R.Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia. PLoS Comput Biol. 2011 Nov;7(11):e1002267.
  • Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, Aliaga C, Dewey A, Rogers A, Loughran K, Hirsch L, Jarbadan NR, Baab KT, Liao J, Wang HG, Kester M, Desai D, Amin S, Loughran Jr. TP, Liu X. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 2011 Sep 8;118(10):2793-800.
  • Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan SF, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran Jr. TP. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood. 2010 Nov 18;116(20):4192-201.